| scholarly article | Q13442814 |
| P50 | author | Vanessa Deschoolmeester | Q40933684 |
| Jolien Van den Bossche | Q40933783 | ||
| Julie Jacobs | Q59662550 | ||
| An Wouters | Q38324398 | ||
| Filip Lardon | Q38324438 | ||
| Ken Op de Beeck | Q38641314 | ||
| P2093 | author name string | Christian Rolfo | |
| Patrick Pauwels | |||
| Marc Peeters | |||
| Karen Zwaenepoel | |||
| Jan Van Meerbeeck | |||
| Christophe Deben | |||
| P2860 | cites work | Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53. | Q40359830 |
| A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans | Q40490424 | ||
| Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. | Q40581450 | ||
| Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro | Q40623595 | ||
| Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies | Q40661602 | ||
| Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. | Q41350117 | ||
| Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer | Q46892013 | ||
| HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. | Q52581241 | ||
| p53-dependent pathways of apoptosis | Q77099494 | ||
| Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors | Q81489492 | ||
| Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy | Q24651380 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models | Q27683975 | ||
| Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme | Q28477660 | ||
| ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis | Q28575693 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. | Q30358684 | ||
| Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer | Q33331636 | ||
| Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study | Q33403930 | ||
| Small-molecule inhibitors of MDM2 as new anticancer therapeutics | Q33515500 | ||
| Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment | Q33533630 | ||
| Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation | Q33808489 | ||
| MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines | Q33915624 | ||
| Cellular Responses to Cisplatin‐Induced DNA Damage | Q34089685 | ||
| Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays | Q34456201 | ||
| Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy | Q34478557 | ||
| The MDM2 gene amplification database | Q34672224 | ||
| Awakening guardian angels: drugging the p53 pathway | Q35014385 | ||
| Drugging the p53 pathway: understanding the route to clinical efficacy | Q38191796 | ||
| Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach | Q38996797 | ||
| Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma | Q39242233 | ||
| Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells | Q39282673 | ||
| Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells | Q39840685 | ||
| PRIMA-1 reactivates mutant p53 by covalent binding to the core domain | Q39857551 | ||
| Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. | Q40200606 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cisplatin | Q412415 |
| lung cancer | Q47912 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 22666-22679 | |
| P577 | publication date | 2015-06-10 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer | |
| P478 | volume | 6 |
| Q59192395 | 10-Gingerol as an inducer of apoptosis through HTR1A in cumulus cells: In-vitro and in-silico studies |
| Q37706478 | Amplification of ACK1 promotes gastric tumorigenesis via ECD-dependent p53 ubiquitination degradation |
| Q90298995 | An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma |
| Q89735096 | Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill |
| Q36951261 | Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles. |
| Q92879104 | Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs |
| Q89408783 | Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier |
| Q47151581 | Ginseng Rh2 protects endometrial cells from oxygen glucose deprivation/re-oxygenation |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q53691994 | Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. |
| Q93110960 | Hypoxia‑induced internalization of connexin 26 and connexin 43 in pulmonary epithelial cells is involved in the occurrence of non‑small cell lung cancer via the P53/MDM2 signaling pathway |
| Q90749220 | Improving anticancer activity towards colon cancer cells with a new p53-activating agent |
| Q64073233 | In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53 |
| Q38619011 | MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients. |
| Q89807991 | MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling |
| Q60045106 | MDM2 inhibitor ameliorates cisplatin-induced nephropathy via NFκΒ signal inhibition |
| Q64114397 | MDM2 promotes epithelial-mesenchymal transition through activation of Smad2/3 signaling pathway in lung adenocarcinoma |
| Q54218400 | Mycoplasma hyorhinis reduces sensitivity of human lung carcinoma cells to Nutlin-3 and promotes their malignant phenotype. |
| Q37696208 | Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma |
| Q38784684 | P53 suppresses ribonucleotide reductase via inhibiting mTORC1. |
| Q36396832 | Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy. |
| Q91643126 | Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status |
| Q38789263 | Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells |
| Q38729732 | Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer |
| Q45823361 | Targeting cyclophilin-D by compound 19 protects neuronal cells from oxygen glucose deprivation/re-oxygenation |
| Q47110143 | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells |
| Q90734672 | The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells |
| Q28072553 | The role of p53 in cancer drug resistance and targeted chemotherapy |
| Q64290120 | ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation |
Search more.